雷贝拉唑三联治疗幽门螺杆菌相关性消化性溃疡疗效观察

目的观察雷贝拉唑联用呋喃唑酮、克拉霉素治疗幽门螺杆菌（Hp）相关性消化性溃疡的疗效。方法胃镜检查确认消化性溃疡且13C尿素呼气试验Hp阳性的86例患者，随机分为治疗组（A组）和对照组（B组）各43例；A组口服雷贝拉唑、呋喃唑酮、克拉霉素治疗，B组将A组方案中的雷贝拉唑替换为奥美拉唑。结果两组治疗7d后症状改善率分别为97．67％和88．38％，Hp根治率分别为90．70％和67．44％，两组在症状改善率和Hp根治率上差异有统计学意义（P〈0．05）。结论雷贝拉唑三联治疗Hp相关性消化性溃疡在缓解症状、根除Hp较其他方案有更佳的效价比。

Efficacy of rabeprazole based triple therapy in the treatment of helicobacter pylori-related peptic ulcer

Objective To observe the efficacy of rabeprazole,furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer.Methods Eighty-six patients with peptic ulcer and Hp infection by endoscopic examination and urea breath test were randomized to treatment group(group A) and control group(group B) with 43 cases in each.Group A took orally rabeprazole,furazolidone and clarithromycin;Group B changed rabeprazole of group A to omeprazole,and others medicine had no change.Results Symptomatic relief was found 97.67% and 88.38% in two groups after 7 days,Hp eradication rate was 90.70% and 67.44%;Symptomatic relief rate and Hp eradication rate of two groups were significantly different(P<0.05).Conclusion Rabeprazole,furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer has good efficacy and low cost.